TG Therapeutics (TGTX) Financial Statements & Analysis

TG Therapeutics (TGTX) Income Statement

TG Therapeutics reported revenue of $616.29M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 87.3% from $329.00M a year earlier. Net income was $447.18M, up 1812.4% year over year, a net margin of 72.6%. Gross margin was 83.7% and operating margin 20.0%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $240.34M, up 70.3% from the same quarter a year earlier.

TG Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

TG Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	616.29	329.00	233.66	2.79	6.69	0.15	0.15	0.15	0.15
Cost of Revenue	100.71	38.49	14.13	0.27	0.79	0.00	0.00	0.09	0.08
Gross Profit	515.57	290.52	219.53	2.52	5.90	0.15	0.15	0.06	0.07
Operating Expenses
Research & Development	160.22	94.29	76.19	125.35	222.58	165.90	154.18	153.79	96.89
Selling, General & Administrative	232.03	154.30	122.71	95.48	128.09	107.85	15.03	15.16	16.33
Operating Expenses	392.25	248.59	198.90	220.84	350.67	273.75	169.21	174.55	118.86
Operating Income	123.32	41.93	20.63	-218.32	-344.77	-273.59	-169.06	-174.40	-118.71
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.86	0.29
Interest Expense	26.73	24.03	12.62	10.19	-5.64	6.33	5.29	1.73	1.14
Other Income/Expense	-15.93	7.69	-7.57	-5.50	-3.33	-5.79	-3.82	0.92	0.24
Income
Income Before Tax	107.39	25.59	13.06	-223.81	-348.10	-279.38	-172.87	-173.48	-118.48
Income Tax Expense	339.79	2.21	0.39	0.00	0.00	0.00	0.00	-0.92	-0.24
Net Income	447.18	23.38	12.67	-223.81	-348.10	-279.38	-172.87	-173.48	-118.48
Net Income - Continuous Operations	447.18	23.38	12.67	-223.81	-348.10	-279.38	-172.87	-173.48	-118.48
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	123.38	49.90	26.10	-213.11	-344.49	-272.68	-167.30	-173.39	-118.39
EBIT	123.32	49.62	20.63	-213.62	-344.77	-273.59	-	-	-
Depreciation & Amortization	0.24	0.28	0.42	0.52	0.28	0.37	0.28	0.09	0.08
Earnings Per Share
Basic EPS	3.00	-	-	-1.00	-3.00	-2.00	-2.00	-2.00	-2.00
Diluted EPS	3.00	-	-	-1.00	-3.00	-2.00	-2.00	-2.00	-2.00
Basic Shares Outstanding	144.32	145.32	141.96	135.41	132.22	115.33	88.37	75.47	62.07
Diluted Shares Outstanding	161.41	160.34	148.51	135.41	132.22	115.33	88.37	75.47	62.07

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TG Therapeutics Financial Statements

What was TG Therapeutics's revenue in fiscal 2025?

TG Therapeutics reported revenue of $616.29M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 87.3% from $329.00M a year earlier.

Is TG Therapeutics profitable?

Yes. TG Therapeutics earned net income of $447.18M in fiscal 2025, a net margin of 72.6%. In fiscal 2024 it earned $23.38M.

What is TG Therapeutics's operating margin?

TG Therapeutics's operating income was $123.32M on revenue of $616.29M in fiscal 2025, an operating margin of 20.0%, compared with 12.7% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition